Autologous Graft vs Collagen Dural Substitute: Time and Donor Sites

Autologous dural grafts such as pericranium or fascia have no purchase cost and introduce no foreign material, but they must be harvested, which takes operative time and sometimes a second incision. Off-the-shelf collagen grafts avoid harvesting and come in standard sizes, at a purchase cost. Most surgeons use both, depending on the case.

The comparison between the patient's own tissue and a manufactured graft is one of the oldest in dural repair, and it comes up in almost every value-analysis discussion about dural substitutes. Finance teams ask why the hospital should pay for a graft when the surgeon could use the patient's tissue for free. This article sets out the honest answer, so that distributors and clinical champions can discuss it without overstating either side.

What autologous options do surgeons use?

The most common autologous materials for dural repair are:

• Pericranium, harvested from the same scalp exposure in many cranial procedures.
• Temporalis fascia, available near many cranial approaches.
• Fascia lata, taken from the thigh through a separate incision when a larger piece is needed.
• Fat and muscle, used more as filling or sealing layers than as a dural replacement.
• Local tissue in spinal surgery, such as fat or fascia from the wound.

Each has a place. Pericranium is especially attractive when the scalp is already open and the tissue is healthy. Fascia lata gives a larger, robust piece, at the cost of a second surgical site.

What are the advantages of autologous tissue?

The case for autologous tissue is real and should be stated fairly. It is the patient's own tissue, so there is no question of animal origin or synthetic composition. It has no purchase price. Surgeons have used it for generations, and many are highly skilled at harvesting and placing it. In some cases, especially where a vascularized flap of pericranium is used in skull base reconstruction, it offers properties a free graft cannot.

A distributor of collagen grafts gains nothing by denying these advantages. Surgeons who use pericranium routinely know exactly why they do it, and they will judge a rep by whether the rep acknowledges it. Starting the conversation by recognizing the value of autologous tissue usually makes the surgeon more willing to discuss the cases where it is less convenient.

What are the limitations of autologous tissue?

The limitations are equally real:

Harvest time

Harvesting a graft takes time, which varies with the tissue and the surgeon. Pericranium from an already-exposed scalp may take little extra time; fascia lata through a separate thigh incision takes more, including closure of the donor site.

Donor-site concerns

A separate harvest site is an additional wound, with the possibility of pain, hematoma, infection or a cosmetic concern at that site. These are generally well managed, but they are part of the comparison.

Availability and size

Autologous tissue is not always available in the quantity or quality needed. In redo surgery, the pericranium may be scarred or already used. In trauma, the scalp may be damaged. In large defects, there may simply not be enough local tissue. In spinal surgery, especially through small exposures, suitable tissue may be limited.

What does an off-the-shelf collagen graft change?

An off-the-shelf collagen graft is available in standard sizes without harvesting. The surgeon chooses a size, the circulator opens it, and it is ready for use as described in the IFU. There is no second incision.

DESU makes two such grafts from pure Type I bovine collagen. DURASHEET is a suturable dural graft matrix usable on both surfaces. DECOLL is intended for onlay use. Both come in four sizes and are supplied ready to use and gamma sterilized.

The trade-offs are a purchase cost, the presence of an animal-derived implant that should be disclosed at consent, and the need for the hospital to stock and manage the product.

There is also a consistency argument, which surgeons sometimes raise themselves. An off-the-shelf graft is the same each time: the same material, the same sizes, the same handling. Autologous tissue varies from patient to patient, in thickness, quality and size. Many surgeons are entirely comfortable with that variation; others value a predictable product in cases where the local tissue is poor.

How should operative time be discussed without inventing numbers?

Value-analysis teams like numbers, and it is tempting to quote a figure for the time saved by avoiding harvest. Unless that figure comes from the hospital's own data or from a published source that clearly applies, do not quote it. Operating time varies widely between surgeons, procedures and patients.

A better approach is to let the department answer the question for itself. Ask the surgeons how long harvesting usually takes them for each tissue and in which cases they would rather not harvest. Ask the OR manager how the hospital values operating room time. With those inputs, the committee can make its own estimate, and it will trust that estimate far more than one offered by a supplier.

In which cases do surgeons tend to choose an off-the-shelf graft?

Surgeons decide case by case, but some patterns come up repeatedly in conversation:

• Large defects, where local tissue would not be enough.
• Redo surgery, where pericranium has been used or is scarred.
• Trauma, where the scalp may be damaged or time is critical.
• Spinal durotomies, where suitable autologous tissue may be scarce in the exposure.
• Cases where the surgeon wishes to avoid a second incision.

Equally, many surgeons continue to prefer autologous tissue when it is readily available, for example pericranium in an elective craniotomy. Some combine the two, using autologous tissue in one layer and a collagen graft in another. A good product rep accepts that and positions the collagen graft as the option for the cases where harvesting is less attractive.

How does this play out in value analysis?

The finance argument usually runs: "Autologous is free, so why buy a graft?" The answer is that autologous tissue is not always available or appropriate, and that the surgeon's time and the patient's donor site are part of the cost picture. The committee does not need to be convinced that a collagen graft should replace autologous tissue; it needs to see that having a ready-to-use option for specific cases is reasonable.

Committees may also ask about consent and documentation. An implanted graft is recorded in the patient's record with its lot number, and its material is part of the consent discussion. Autologous tissue needs neither a lot number nor a supplier. These are small administrative differences, but they are part of the picture and should be mentioned openly.

A short statement from the surgeon, listing the cases where they would use an off-the-shelf graft, is usually the most persuasive evidence. Combine it with the product documentation and a sensible size mix, and the request becomes easy to support.

Talk to a DESU product specialist

If you are presenting an off-the-shelf dural graft to a hospital that relies heavily on autologous tissue, DESU's product specialists can supply documentation for DURASHEET and DECOLL, help you frame the comparison fairly and discuss what your market requires. Contact sales@desu.tr, use the contact page, or request a quote.